Drug that targets an inflammatory enzyme could help prevent lung cancer
August 14, 2026
A new study by MIT researchers shows that inhibiting caspase-1 can reduce the risk of tumor growth.
A new study by MIT researchers shows that inhibiting caspase-1 can reduce the risk of tumor growth.
Immunotherapy that targets tumor-associated macrophages, a type of immune cell in the tumor microenvironment, works only if the cells have a functional system of molecules that enables them to respond to the treatment.
Osteoarthritis is a leading cause of chronic pain and disability worldwide. Current intra-articular standards of care, such as analgesics, corticosteroids and viscosupplements, provide only transient symptomatic relief and do not reliably modify disease progression
Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have uncovered a previously unknown mechanism that helps cancer cells evade detection by the body’s immune system.
More than a decade ago, Dr. Matthew Hebb was treating patients with Parkinson’s disease using deep brain stimulation by implanting tiny electrodes into the brain and delivering electrical signals to control tremors. He wondered if the same basic technology could be used against brain cancer.
A compound produced by bacteria in many people’s digestive tracts increases the risk of developing Alzheimer’s disease and speeds cognitive decline in dementia patients, making it a potential target for a treatment that could reduce Alzheimer’s risk, according to a new study published in Nature Communications
Vesalio’s pVasc NET mechanical thrombectomy device integrates clot-capture technology to retain clot fragments during retrieval.
The SimpleScreen test is designed to detect early lung cancer signals from a standard blood sample.
Now, a team led by Wei Gao, a professor in Caltech’s Cherng Department of Medical Engineering, has developed a stick-on patch capable of gathering lipid measurements by analyzing sweat. And it can do so not just once but continuously.
HOUSTON, Aug. 11, 2026 /PRNewswire/ — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,691,147, entitled “Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment.” The patent describes methods utilizing fibroblasts to improve the engraftment and long-term function of transplanted pancreatic islets, addressing one of the major challenges in islet transplantation.